Viral targets for vaccines against COVID-19

Nature Reviews Immunology
21, 73-82
DOI: 10.1038/s41577-020-00480-0

Citation Report

#	Article	IF	Citations
1	Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination. Journal of Korean Medical Science, 2021, 36, e158.	1.1	11
2	The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. International Journal of Biological Sciences, 2021, 17, 1476-1485.	2.6	23
3	Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments. SSRN Electronic Journal, 0, , .	0.4	7
4	Could repurposing existing vaccines and antibiotics help to control the COVID-19 pandemic?. , 2021, , 245-255.		0
5	Safety of COVID-19 vaccines administered in the EU: Should we be concerned?. Toxicology Reports, 2021, 8, 871-879.	1.6	95
6	Older adults: panoramic view on the COVID-19 vaccination. AIMS Public Health, 2021, 8, 388-415.	1.1	14
8	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. Computational and Structural Biotechnology Journal, 2021, 19, 3799-3809.	1.9	24
9	A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines, 2021, 9, 39.	2.1	78
10	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110214.	0.7	29
11	Updated insight into COVID-19 disease and health management to combat the pandemic. , 2021, , 3-39.		6
12	Antibody Titers 3-Months Post-Vaccination with the Pfizer/Biontech Vaccine in Greece. SSRN Electronic Journal, 0, , .	0.4	1
13	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. Vaccines, 2021, 9, 36.	2.1	41
15	Specific measures to response pandemic of COVID-19 in China: a systematic review. E3S Web of Conferences, 2021, 292, 03076.	0.2	0
17	Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2. Vaccines, 2021, 9, 178.	2.1	23
18	COVID-19 vaccines: implementation, limitations and opportunities. Global Health & Medicine, 2021, 3, 1-5.	0.6	28
20	Making sense of spike D614G in SARS-CoV-2 transmission. Science China Life Sciences, 2021, 64, 1062-1067.	2.3	8
23	SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids. International Journal of Molecular Sciences, 2021, 22, 2356.	1.8	13
24	COVID-19 mRNA vaccines. Journal of Genetics and Genomics, 2021, 48, 107-114.	1.7	59

#	Article	IF	Citations
25	Mutational hotspots and conserved domains of SARS-CoV-2 genome in African population. Beni-Suef University Journal of Basic and Applied Sciences, 2021, 10, 11.	0.8	14
30	Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection. Pharmaceutics, 2021, 13, 342.	2.0	8
35	Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response. Biomicrofluidics, 2021, 15, 021501.	1.2	14
37	Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins. Asian Journal of Pharmaceutical Sciences, 2021, 16, 263-264.	4.3	8
39	Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology, 2021, 12, 654165.	2.2	33
40	Opposing vaccine hesitancy during the COVID-19 pandemic - A critical commentary and united statement of an international osteopathic research community. International Journal of Osteopathic Medicine, 2021, 39, A1-A6.	0.4	4
41	SARS-CoV-2 - SYNOPTIC CHART OF THE MAIN CHARACTERISTICS OF VIRUS, PATHOGENESIS, IMMUNE RESPONSE, IMMUNOPROPHYLAXIS. Roumanian Archives of Microbiology and Immunology, 2021, 80, 51-80.	0.1	1
45	Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies. Seminars in Immunopathology, 2021, 43, 383-392.	2.8	36
46	Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19. , 0, , .		0
47	Exaptation of Retroviral Syncytin for Development of Syncytialized Placenta, Its Limited Homology to the SARS-CoV-2 Spike Protein and Arguments against Disturbing Narrative in the Context of COVID-19 Vaccination. Biology, 2021, 10, 238.	1.3	18
49	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021, 7, 512-533.	5.3	217
51	Transgene Delivery to Human Induced Pluripotent Stem Cells Using Nanoparticles. Pharmaceuticals, 2021, 14, 334.	1.7	3
55	COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy. Neurology: Clinical Practice, 2021, 11, 358-361.	0.8	14
56	Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Reviews Immunology, 2021, 21, 382-393.	10.6	568
57	Deepening of In Silico Evaluation of SARS-CoV-2 Detection RT-qPCR Assays in the Context of New Variants. Genes, 2021, 12, 565.	1.0	26
58	Neutralizing Antibody Therapeutics for COVID-19. Viruses, 2021, 13, 628.	1.5	99
64	In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (Mpro) Inhibitors. Molecules, 2021, 26, 2082.	1.7	39
65	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Frontiers in Immunology, 2021, 12, 669339.	2.2	81

#	Article	IF	Citations
66	RBD targeted COVID vaccine and full length spike-protein vaccine (mutation and glycosylation role) relationship with procoagulant effect. , 2021, 5, 001-008.		0
67	The Transmission of SARS-CoV-2 Infection on the Ocular Surface and Prevention Strategies. Cells, 2021, 10, 796.	1.8	22
68	Distinct antibody and memory B cell responses in SARS-CoV-2 naÃ¯ve and recovered individuals after mRNA vaccination. Science Immunology, 2021, 6, .	5.6	556
69	Oral Mucosa, Saliva, and COVID-19 Infection in Oral Health Care. Frontiers in Medicine, 2021, 8, 656926.	1.2	29
70	Impact of Ribosome Activity on SARS-CoV-2 LNP â€“ Based mRNA Vaccines. Frontiers in Molecular Biosciences, 2021, 8, 654866.	1.6	10
74	Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1585-1591.	1.4	47
76	Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice. Microbial Cell Factories, 2021, 20, 95.	1.9	23
77	SARS-CoV-2 nanobodies 2.0. Signal Transduction and Targeted Therapy, 2021, 6, 202.	7.1	6
79	Evidence of the presence of SARSâ€CoVâ€2 virus in atmospheric air and surfaces of a dedicated COVID hospital. Journal of Medical Virology, 2021, 93, 5339-5349.	2.5	17
80	Clinical Characteristics of Foreign-Imported COVID-19 Cases in Xiâ€™an, China. International Journal of General Medicine, 2021, Volume 14, 2069-2078.	0.8	1
81	Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. Vaccines, 2021, 9, 466.	2.1	30
82	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. International Reviews of Immunology, 2021, , 1-16.	1.5	6
83	Brief review of the mRNA vaccines COVID-19. Inflammopharmacology, 2021, 29, 645-649.	1.9	42
84	2019 Coronavirus disease (COVID-19): contribution of rheumatology. Terapevticheskii Arkhiv, 2021, 93, .	0.2	6
85	Design of an effective piezoelectric microcantilever biosensor for rapid detection of COVID-19. Journal of Medical Engineering and Technology, 2021, 45, 423-433.	0.8	13
86	Rotavirus as an Expression Platform of Domains of the SARS-CoV-2 Spike Protein. Vaccines, 2021, 9, 449.	2.1	17
87	Micronutrient therapy and effective immune response: a promising approach for management of COVID-19. Infection, 2021, 49, 1133-1147.	2.3	10
88	Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties. Viruses, 2021, 13, 1221.	1.5	9

#	Article	IF	Citations
89	A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects. Frontiers in Genetics, 2021, 12, 684152.	1.1	10
92	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. ACS Central Science, 2021, 7, 1191-1204.	5.3	34
94	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Science Translational Medicine, 2021, 13, .	5.8	198
95	SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology, 2021, 19, 409-424.	13.6	2,650
96	How May Obesity-Induced Oxidative Stress Affect the Outcome of COVID-19 Vaccines? Lesson Learned from the Infection. Stresses, 2021, 1, 119-122.	1.8	3
97	The Status and Prospects of Epsteinâ€“Barr Virus Prophylactic Vaccine Development. Frontiers in Immunology, 2021, 12, 677027.	2.2	23
98	Updates on the coronavirus disease 2019 vaccine and consideration in children. Clinical and Experimental Pediatrics, 2021, 64, 328-338.	0.9	8
99	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nature Communications, 2021, 12, 3587.	5.8	71
100	Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PLPRO and 3CLPRO proteases. European Journal of Pharmacology, 2021, 901, 174082.	1.7	30
101	Spike D614G â€" A Candidate Vaccine Antigen Against Covid-19. New England Journal of Medicine, 2021, 384, 2349-2351.	13.9	12
102	De novo ssRNA Aptamers against the SARS-CoV-2 Main Protease: In Silico Design and Molecular Dynamics Simulation. International Journal of Molecular Sciences, 2021, 22, 6874.	1.8	8
103	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science, 2021, 373, 642-648.	6.0	211
105	pâ€cymene impairs SARSâ€CoVâ€2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARSâ€CoVâ€2 nucleocapsid protein and H1N1 nucleoprotein. Pharmacology Research and Perspectives, 2021, 9, e00798.	1.1	15
106	Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3575-3583.	2.0	41
107	Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion Mechanism. Viruses, 2021, 13, 1126.	1.5	9
108	Structural basis of coronavirus E protein interactions with human PALS1 PDZ domain. Communications Biology, 2021, 4, 724.	2.0	37
109	Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today, 2021, 38, 101142.	6.2	170
110	Post-vaccination cases of COVID-19 among healthcare workers at Siloam Teaching Hospital, Indonesia. International Journal of Infectious Diseases, 2021, 107, 268-270.	1.5	19

#	Article	IF	Citations
111	Multiple Roles of SARS-CoV-2 N Protein Facilitated by Proteoform-Specific Interactions with RNA, Host Proteins, and Convalescent Antibodies. Jacs Au, 2021, 1, 1147-1157.	3.6	28
112	Machine Learning Reveals the Critical Interactions for SARS-CoV-2 Spike Protein Binding to ACE2. Journal of Physical Chemistry Letters, 2021, 12, 5494-5502.	2.1	44
113	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. Signal Transduction and Targeted Therapy, 2021, 6, 226.	7.1	103
115	A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. Pathogens, 2021, 10, 788.	1.2	46
116	Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Viruses, 2021, 13, 1421.	1.5	6
117	Vaccinations and Autoimmune Diseases. Vaccines, 2021, 9, 815.	2.1	45
120	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Science Immunology, 2021, 6, .	5.6	53
121	Specific allelic discrimination of N501Y and other SARSâ€CoVâ€2 mutations by ddPCR detects B.1.1.7 lineage in Washington State. Journal of Medical Virology, 2021, 93, 5931-5941.	2.5	31
122	Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients. Vaccines, 2021, 9, 714.	2.1	25
123	Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses. Vaccines, 2021, 9, 733.	2.1	4
125	Lessons Learned from Cutting-Edge Immunoinformatics on Next-Generation COVID-19 Vaccine Research. International Journal of Peptide Research and Therapeutics, 2021, 27, 2303-2311.	0.9	6
126	The SARS CoV-2 spike domain, RGD and integrin binding effect-relationship for vaccine design strategy. Annals of Proteomics and Bioinformatics, 2021, 5, 027-041.	1.0	0
127	ÐšÐ¾Ñ€Ð¾Ð½Ð°Ð²Ñ–Ñ€ÑƒÑ 1 S-Ð°Ð½Ñ‚Ð¸Ð³ÐµÐ½ Ñ‰Ð¾ Ð¼Ð°Ñ€ÐºÐµÑ€ ÐµÑ„ÐµÐºÑ‚Ð¸Ð²Ð½Ð¾Ñ— Ð²Ð°ÐºÑ†Ð¸Ð½Ð¾Ñ—		
128	A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. Npj Vaccines, 2021, 6, 91.	2.9	19
129	Coronavirus disease 2019 vaccines: perspectives and update. Medical Journal Armed Forces India, 2021, 77, S245-S249.	0.3	1
132	Secreted Expression of mRNAâ€Encoded Truncated ACE2 Variants for SARSâ€CoVâ€2 via Lipidâ€Like Nanoassemblies. Advanced Materials, 2021, 33, e2101707.	11.1	19
133	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. ACS Central Science, 2021, 7, 1368-1380.	5.3	21
134	Modulation of Host Immune Response Is an Alternative Strategy to Combat SARS-CoV-2 Pathogenesis. Frontiers in Immunology, 2021, 12, 660632.	2.2	12

#	Article	IF	Citations
135	COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines. Infectious Disease Reports, 2021, 13, 685-699.	1.5	72
136	Antimicrobial immunotherapeutics: past, present and future. Emerging Topics in Life Sciences, 2021, 5, 609-628.	1.1	1
137	Analysis of the dynamic relationship between immune profiles and the clinical features of patients with COVID-19. Annals of Translational Medicine, 2021, 9, 1118-1118.	0.7	3
138	Inhalable nanocatchers for SARS-CoV-2 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	34
139	Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist. Journal of Medicinal Chemistry, 2021, 64, 11554-11569.	2.9	9
140	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. International Immunopharmacology, 2021, 96, 107763.	1.7	35
141	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. Biochemical Journal, 2021, 478, 2405-2423.	1.7	46
142	The need for broadly protective COVID-19 vaccines: Beyond S-only approaches. Vaccine, 2021, 39, 4239-4241.	1.7	14
143	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease. Biochemical Journal, 2021, 478, 2465-2479.	1.7	43
144	Scientists have favorable opinions on immunity certificates but raise concerns regarding fairness and inequality. Scientific Reports, 2021, 11, 14016.	1.6	19
146	The role of micronutrient and immunomodulation effect in the vaccine era of COVID-19. Journal of the Chinese Medical Association, 2021, 84, 821-826.	0.6	19
147	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. Vaccines, 2021, 9, 836.	2.1	15
148	Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases. Expert Review of Respiratory Medicine, 2021, 15, 1035-1048.	1.0	14
152	DNA Vaccine Administered by Cationic Lipoplexes or by In Vivo Electroporation Induces Comparable Antibody Responses against SARS-CoV-2 in Mice. Vaccines, 2021, 9, 874.	2.1	16
154	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nature Microbiology, 2021, 6, 1188-1198.	5.9	314
155	SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection, 2021, 49, 855-876.	2.3	61
156	SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. Microorganisms, 2021, 9, 1744.	1.6	16
157	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infectious Diseases, The, 2021, 21, 1107-1119.	4.6	345

#	Article	IF	Citations
158	An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. Cell and Bioscience, 2021, 11, 164.	2.1	10
159	Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2022, 94, 178-185.	2.5	2
160	Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. Pathogens, 2021, 10, 1051.	1.2	18
161	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. Cell Discovery, 2021, 7, 67.	3.1	29
164	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. Viruses, 2021, 13, 1693.	1.5	69
165	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	5.8	150
166	SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites. International Journal of Molecular Sciences, 2021, 22, 9035.	1.8	41
167	Neutralization of SARSâ€CoVâ€2 by highly potent, hyperthermostable, and mutationâ€tolerant nanobodies. EMBO Journal, 2021, 40, e107985.	3.5	69
168	Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters. Frontiers in Microbiology, 2021, 12, 722178.	1.5	5
169	Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19. Pathogens, 2021, 10, 1048.	1.2	45
170	Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry. Vaccine, 2021, 39, 5106-5115.	1.7	12
171	Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021. Drug Discoveries and Therapeutics, 2021, 15, 222-224.	0.6	16
172	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. International Journal of Molecular Sciences, 2021, 22, 8498.	1.8	11
173	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. International Immunopharmacology, 2021, 97, 107679.	1.7	9
174	Disappearance of Seasonal Respiratory Viruses in Children Under Two Years Old During COVID-19 Pandemic: A Monocentric Retrospective Study in Milan, Italy. Frontiers in Pediatrics, 2021, 9, 721005.	0.9	38
175	Cell-Free Glycoengineering of the Recombinant SARS-CoV-2 Spike Glycoprotein. Frontiers in Bioengineering and Biotechnology, 2021, 9, 699025.	2.0	5
176	mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors. Future Virology, 2021, , .	0.9	2
177	Parental psychological distress and attitudes towards COVID-19 vaccination: A cross-sectional survey in Shenzhen, China. Journal of Affective Disorders, 2021, 292, 552-558.	2.0	49

#	Article	IF	Citations
178	Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccineâ€induced thrombotic thrombocytopenia (VITT). Journal of Leukocyte Biology, 2021, , .	1.5	19
179	Persistent High Percentage of HLA-DR+CD38high CD8+ T Cells Associated With Immune Disorder and Disease Severity of COVID-19. Frontiers in Immunology, 2021, 12, 735125.	2.2	35
180	Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA. Molecular Biomedicine, 2021, 2, 29.	1.7	10
181	Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients. Briefings in Bioinformatics, 2022, 23, .	3.2	14
182	Will achieving herd immunity be a road to success to end the COVID-19 pandemic?. Journal of Infection, 2021, 83, 381-412.	1.7	22
183	The Endocannabinoid System as Prognostic Biomarker of the Obstructive Sleep Apnea Morbidity in COVID-19-Recovered Individuals. Sleep and Vigilance, 2021, 5, 205-211.	0.4	0
184	Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Bioscience Reports, 2021, 41, .	1.1	28
185	Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice. Vaccines, 2021, 9, 978.	2.1	20
186	Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. Frontiers in Immunology, 2021, 12, 652252.	2.2	13
187	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Cell Discovery, 2021, 7, 82.	3.1	22
188	Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2. Journal of Clinical Virology, 2021, 142, 104912.	1.6	8
189	Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19. International Journal of Pharmaceutics, 2021, 607, 121024.	2.6	9
190	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. PLoS ONE, 2021, 16, e0257191.	1.1	19
191	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 2021, 33, 529-540.	1.8	28
192	COVID-19 vaccine candidates and vaccine development platforms available worldwide. Journal of Pharmaceutical Analysis, 2021, 11, 675-682.	2.4	8
193	Vaccinomics: a future avenue for vaccine development against emerging pathogens. Expert Review of Vaccines, 2021, 20, 1561-1569.	2.0	18
197	A study protocol to prepare an RBD protein for vaccine against COVID-19. F1000Research, 0, 10, 943.	0.8	0
198	Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. Biomaterials, 2021, 278, 121159.	5.7	23

#	Article	IF	Citations
199	Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities. International Journal of Infectious Diseases, 2021, 111, 68-75.	1.5	9
200	A one-step real-time RT-PCR assay for simultaneous typing of SARS-CoV-2 mutations associated with the E484K and N501Y spike protein amino-acid substitutions. Journal of Virological Methods, 2021, 296, 114242.	1.0	10
201	Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. Lancet Microbe, The, 2021, 2, e494.	3.4	45
202	Structure of SARS-CoV-2 spike protein. Current Opinion in Virology, 2021, 50, 173-182.	2.6	122
203	Know your enemy and know yourself â€“ the case of SARS-CoV-2 host factors. Current Opinion in Virology, 2021, 50, 159-170.	2.6	9
204	From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic. Environmental Research, 2021, 201, 111555.	3.7	8
205	Cardiac arrest secondary to Covid19 pneumonia post full vaccination. American Journal of Emergency Medicine, 2021, 49, 257-258.	0.7	3
206	Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. Journal of Virological Methods, 2021, 297, 114271.	1.0	88
207	COVID-19 vaccines: Current evidence and considerations. Metabolism Open, 2021, 12, 100124.	1.4	32
208	COVID-19 challenges: From SARS-CoV-2 infection to effective point-of-care diagnosis by electrochemical biosensing platforms. Biochemical Engineering Journal, 2021, 176, 108200.	1.8	17
209	TB or not to be: what specificities and impact do antibodies have during tuberculosis?. Oxford Open Immunology, 2021, 2, .	1.2	4
210	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerging Microbes and Infections, 2021, 10, 1574-1588.	3.0	18
211	A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. RSC Advances, 2021, 11, 20006-20035.	1.7	6
212	Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. Immune Network, 2021, 21, e8.	1.6	3
213	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. Pediatric Infection and Vaccine, 2021, 28, 7.	0.1	7
214	The emerging SARS-CoV-2 variants of concern. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110243.	1.1	82
216	From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, Then Clot Blood Cells in Pulmonary and Systemic Microvasculature. SSRN Electronic Journal, 0, , .	0.4	4
217	COVID-19 Expands Its Territories from Humans to Animals. China CDC Weekly, 2021, 3, 855-858.	1.0	24

#	Article	IF	Citations
218	Global Prevalence of Adaptive and Prolonged Infectionsâ€™ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Viruses, 2021, 13, 1974.	1.5	9
219	Genetic diversity of SARS-CoV-2 in South America: demographic history and structuration signals. Archives of Virology, 2021, 166, 3357-3371.	0.9	3
220	Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA. Journal of Molecular Cell Biology, 2021, 13, 748-759.	1.5	10
221	Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Bioanalysis, 2021, 13, 1805-1826.	0.6	11
222	Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells. Viruses, 2021, 13, 2021.	1.5	35
223	Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen. Translational Research, 2022, 240, 26-32.	2.2	12
224	Perceptions Regarding COVID-19 Vaccination Among a Representative Pakistani Population Coming to Tertiary Care Cardiac Hospital. Cureus, 2021, 13, e18654.	0.2	3
225	MonoklonÃ¡lis antitestek Ã©s egyÃ©b biolÃ³giai terÃ¡piÃ¡k a COVIDâ€“19 kezelÃ©sÃ©re. Scientia Et Securitas, 2021, 2, 200-206.	0.1	0
226	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. Cell Reports, 2021, 37, 109869.	2.9	59
227	WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe, The, 2022, 3, e235-e240.	3.4	108
228	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. Seminars in Immunology, 2021, 55, 101508.	2.7	37
230	Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice. Cell Discovery, 2021, 7, 91.	3.1	12
232	Single-cell profiling of proteins and chromatin accessibility using PHAGE-ATAC. Nature Biotechnology, 2022, 40, 374-381.	9.4	31
233	Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey. Journal of Integrative Medicine, 2022, 20, 34-44.	1.4	52
235	Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Microbiology Spectrum, 2021, 9, e0135221.	1.2	13
236	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. Environmental Science and Pollution Research, 2021, 28, 68071-68089.	2.7	15
237	The trend of Hong Kong confirmed cases after starting COVID-19 vaccination plan. Microbes and Infectious Diseases, 2021, .	0.0	0
238	Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. Biologics, 2021, 1, 337-356.	2.3	58

#	Article	IF	Citations
239	SCovid: single-cell atlases for exposing molecular characteristics of COVID-19 across 10 human tissues. Nucleic Acids Research, 2022, 50, D867-D874.	6.5	28
241	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	5.8	18
242	Does the EU COVID Digital Certificate Strike a Reasonable Balance between Mobility Needs and Public Health?. Medicina (Lithuania), 2021, 57, 1077.	0.8	9
243	In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine. Molecules, 2021, 26, 6182.	1.7	23
244	A pathogen-like antigen based vaccine confers immune protection against SARS-CoV-2 in non-human primates. Cell Reports Medicine, 2021, 2, 100448.	3.3	11
246	Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2. Annals of Neurosciences, 2021, 28, 201-218.	0.9	7
247	Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses. Journal of Experimental Medicine, 2021, 218, .	4.2	17
248	COVID-19 Vaccine Booster: To Boost or Not to Boost. Infectious Disease Reports, 2021, 13, 924-929.	1.5	78
249	Factors associated with COVID-19 vaccination acceptance among industrial workers in the post-vaccination era: a large-scale cross-sectional survey in China. Human Vaccines and Immunotherapeutics, 2024, 17, 5069-5075.	1.4	8
250	SARSâ€CoVâ€2â€“host proteome interactions for antiviral drug discovery. Molecular Systems Biology, 2021, 17, e10396.	3.2	53
251	Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants. Vaccine, 2021, 39, 7001-7011.	1.7	20
252	Multicomponent vaccines to fight SARS-CoV-2 variants of concern. Vaccine, 2021, 39, 6969-6971.	1.7	4
253	An easy pipeline for one-step purification of SARS-CoV-2 nucleocapsid protein from insect cell suspension culture. Journal of Virological Methods, 2022, 299, 114341.	1.0	5
255	Science-based COVID-19 vaccine development. National Science Review, 2021, 8, nwab193.	4.6	17
256	Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain. Scientific Reports, 2021, 11, 21571.	1.6	16
257	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. Scientific Reports, 2021, 11, 21601.	1.6	20
258	Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers. Case Reports in Infectious Diseases, 2021, 2021, 1-4.	0.2	0
259	Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2. VirusDisease, 2021, 32, 703-726.	1.0	15

#	Article	IF	Citations
260	RCSB Protein Data Bank resources for structure-facilitated design of mRNA vaccines for existing and emerging viral pathogens. Structure, 2022, 30, 55-68.e2.	1.6	10
261	Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. Cellular and Molecular Life Sciences, 2021, 78, 7967-7989.	2.4	40
262	An insight into the simulation directed understanding of the mechanism in SARS CoV-2 N-CTD, dimer integrity, and RNA-binding: Identifying potential antiviral inhibitors. Journal of Biomolecular Structure and Dynamics, 2022, 40, 13912-13924.	2.0	4
263	Evaluation of a Novel Multiplex Platform for Simultaneous Detection of IgG Antibodies Against the 4 Main SARS-CoV-2 Antigens. journal of applied laboratory medicine, The, 2022, 7, 698-710.	0.6	3
265	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, Ribonuclease I and Human RNase A. Frontiers in Microbiology, 2021, 12, 660149.	1.5	1
266	Safety and immunogenicity of inactivated COVIDâ€19 vaccine in health care workers. Journal of Medical Virology, 2022, 94, 1442-1449.	2.5	23
267	Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice. Vaccines, 2021, 9, 1383.	2.1	4
268	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines, 2021, 9, 1345.	2.1	22
270	Carbon fullerene and nanotube are probable binders to multiple targets of SARS-CoV-2: Insights from computational modeling and molecular dynamic simulation studies. Infection, Genetics and Evolution, 2021, 96, 105155.	1.0	21
271	In-silico design of a multi-epitope for developing sero-diagnosis detection of SARS-CoV-2 using spike glycoprotein and nucleocapsid antigens. Network Modeling Analysis in Health Informatics and Bioinformatics, 2021, 10, 61.	1.2	7
272	The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduction and Targeted Therapy, 2021, 6, 396.	7.1	111
273	Virus neutralisation by intracellular antibodies. Seminars in Cell and Developmental Biology, 2022, 126, 108-116.	2.3	8
274	SARS-CoV-2 Targets and COVID-19 Vaccines. Covid, 2021, 1, 608-621.	0.7	4
275	Herpetic Keratitis Preceded by COVID-19 Vaccination. Vaccines, 2021, 9, 1394.	2.1	16
276	Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12â€“18 Years in Saudi Arabia. Vaccines, 2021, 9, 1297.	2.1	33
277	Integrative Multi-omics Landscape of Non-structural Protein 3 of Severe Acute Respiratory Syndrome Coronaviruses. Genomics, Proteomics and Bioinformatics, 2021, 19, 707-726.	3.0	8
278	Discussing the Efficacy and Safety of Covid-19 Vaccine Available in India- A Mini Review. Shanghai Ligong Daxue Xuebao/Journal of University of Shanghai for Science and Technology, 2021, 23, 330-343.	0.1	0
279	Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis. Scientific Reports, 2021, 11, 22288.	1.6	8

#	Article	IF	Citations
280	Complementary and alternative medicine during COVID-19 pandemic: What we have done. Journal of Integrative Medicine, 2022, 20, 1-3.	1.4	8
281	COVID-19 reinfection: the role of natural immunity, vaccines, and variants. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 733-739.	0.4	22
282	Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies. Cell Discovery, 2021, 7, 112.	3.1	14
283	The Viral Class II Membrane Fusion Machinery: Divergent Evolution from an Ancestral Heterodimer. Viruses, 2021, 13, 2368.	1.5	20
284	SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale. Biochimie, 2022, 195, 86-89.	1.3	4
286	Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduction and Targeted Therapy, 2021, 6, 389.	7.1	21
287	Previous COVID-19 Infection and Antibody Levels After Vaccination. Frontiers in Public Health, 2021, 9, 778243.	1.3	69
288	E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody. International Immunopharmacology, 2022, 102, 108424.	1.7	31
289	Genome Characterization and Potential Risk Assessment of the Novel SARS-CoV-2 Variant Omicron (B.1.1.529). Zoonoses, 2021, 1, .	0.5	38
290	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. Human Vaccines and Immunotherapeutics, 2024, 17, 4714-4740.	1.4	16
291	Temporal variations in country-specific mutational profiles of SARS-CoV-2: effect on vaccine efficacy. Future Virology, 2021, 16, 805-819.	0.9	2
292	Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Journal of Korean Medical Science, 2021, 36, e311.	1.1	33
293	A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features. Current Research in Structural Biology, 2021, 3, 290-300.	1.1	17
294	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. Applied Sciences (Switzerland), 2022, 12, 665.	1.3	8
295	Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. Journal of Autoimmunity, 2022, 127, 102792.	3.0	96
296	A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding. Immunology Letters, 2022, 242, 1-7.	1.1	4
297	Design, synthesis and inÂvitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors. European Journal of Medicinal Chemistry, 2022, 229, 114046.	2.6	41
298	From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene, 2022, 814, 146134.	1.0	97

#	Article	IF	Citations
299	Single-cell immunology of SARS-CoV-2 infection. Nature Biotechnology, 2022, 40, 30-41.	9.4	78
301	Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial. Frontiers in Immunology, 2021, 12, 798117.	2.2	42
302	SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review. Tropical Medicine and Infectious Disease, 2022, 7, 9.	0.9	14
303	Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?. Molecular Neurobiology, 2022, 59, 1850-1861.	1.9	76
304	The "LLQY" motif on SARS-CoV-2 spike protein affects S incorporation into virus particles. Journal of Virology, 2022, , jvi0189721.	1.5	1
305	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
306	Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies. Journal of Microbiology, 2022, 60, 238-246.	1.3	5
308	Extra-Pulmonary Complications in SARS-CoV-2 Infection: A Comprehensive Multi Organ-System Review. Microorganisms, 2022, 10, 153.	1.6	27
309	Association of vitamin D status with COVID-19 and its severity. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 579-599.	2.6	47
310	Genomic surveillance of SARS-CoV-2 in the state of Delaware reveals tremendous genomic diversity. PLoS ONE, 2022, 17, e0262573.	1.1	6
311	Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. Journal of Chemical Information and Modeling, 2022, 62, 412-422.	2.5	507
312	mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine, 2022, 73, 17-39.	5.0	120
313	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. BMC Molecular and Cell Biology, 2022, 23, 2.	1.0	10
314	Designing AbhiSCoVac - A single potential vaccine for all â€˜corona culpritsâ€™: Immunoinformatics and immune simulation approaches. Journal of Molecular Liquids, 2022, 351, 118633.	2.3	20
315	Omicron: the highly mutational COVID-19 variant with immune escape. Pan African Medical Journal, 2022, 41, 84.	0.3	2
317	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine, 2022, 75, 103761.	2.7	104
318	Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint. BMC Medicine, 2022, 20, 36.	2.3	17
319	Next Generation of Transgenic Plants: From Farming to Pharming. , 0, , .		5

#	Article	IF	Citations
320	COVID-19: Non-invasive ventilation in hypoxemic acute respiratory failure. International Journal of Preventive Medicine, 2022, 13, 5.	0.2	0
322	SARSâ€CoVâ€2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. FEBS Journal, 2022, 289, 4240-4250.	2.2	25
323	Quantifying the effect of government interventions and virus mutations on transmission advantage during COVID-19 pandemic. Journal of Infection and Public Health, 2022, 15, 338-342.	1.9	6
324	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. VirusDisease, 2022, 33, 1-22.	1.0	47
325	Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes. Arabian Journal of Chemistry, 2022, 15, 103631.	2.3	1
326	Efficacious nanomedicine track toward combating COVID-19. Nanotechnology Reviews, 2022, 11, 680-698.	2.6	4
327	Virus-specific editing identification approach reveals the landscape of A-to-I editing and its impacts on SARS-CoV-2 characteristics and evolution. Nucleic Acids Research, 2022, 50, 2509-2521.	6.5	23
328	Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2. Molecular Diversity, 2022, 26, 3309-3324.	2.1	17
329	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Science Translational Medicine, 2022, 14, eabi9215.	5.8	123
330	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, 2022, 185, 896-915.e19.	13.5	189
331	COVIDâ€19Â vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€"EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	2.7	12
332	Advanced Materials for SARSâ€CoVâ€2 Vaccines. Advanced Materials, 2022, 34, e2107781.	11.1	25
333	Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patientsâ€"A Target for SARS-CoV-2 Propagation. International Journal of Molecular Sciences, 2022, 23, 1941.	1.8	4
334	Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants. Acta Pharmaceutica Sinica B, 2022, 12, 3187-3194.	5.7	11
335	Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults. Frontiers of Medicine, 2022, 16, 93-101.	1.5	21
336	SARS-CoV-2â€"Specific Vaccine Candidates; the Contribution of Structural Vaccinology. Vaccines, 2022, 10, 236.	2.1	14
337	COVID-19 and arrhythmia: An overview. Journal of Cardiology, 2022, 79, 468-475.	0.8	21
338	Potential of X-ray free-electron lasers for challenging targets in structure-based drug discovery. Drug Discovery Today: Technologies, 2021, 39, 101-110.	4.0	6

#	Article	IF	Citations
340	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opinion on Investigational Drugs, 2022, 31, 41-58.	1.9	26
341	Immune responses in SARS-CoV-2, SARS-CoV, and MERS-CoV infections: A comparative review. International Journal of Preventive Medicine, 2022, 13, 45.	0.2	4
342	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. Theranostics, 2022, 12, 2519-2534.	4.6	3
343	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110566.	0.7	13
344	A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern. Chemical Communications, 2022, 58, 3925-3928.	2.2	9
345	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discovery, 2022, 8, 17.	3.1	23
346	A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Frontiers in Immunology, 2022, 13, 844837.	2.2	13
347	Identification of a Novel Neutralizing Epitope on the N-Terminal Domain of the Human Coronavirus 229E Spike Protein. Journal of Virology, 2022, 96, JVI0195521.	1.5	2
348	Exploring Data and Literature Currently Available on the COVID-19 Vaccines. Journal of Community Hospital Internal Medicine Perspectives, 2022, 12, 7-12.	0.4	1
349	Stem cell therapy for COVID-19 pneumonia. Molecular Biomedicine, 2022, 3, 6.	1.7	7
350	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	7.1	34
351	Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Research, 2022, 32, 375-382.	5.7	21
352	Potent antibody immunity to SARSâ€CoVâ€2 variants elicited by a third dose of inactivated vaccine. Clinical and Translational Medicine, 2022, 12, e732.	1.7	14
353	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. Nature Communications, 2022, 13, 871.	5.8	107
354	Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations. International Journal of Molecular Sciences, 2022, 23, 2078.	1.8	5
355	Inflammatory Sixth Nerve Palsy Post-COVID-19 Vaccination: Magnetic Resonance Imaging Findings. Neuro-Ophthalmology, 2022, 46, 314-318.	0.4	6
356	Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses. Journal of Clinical Medicine, 2022, 11, 1503.	1.0	4
357	Cellular Immunityâ€"The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. Vaccines, 2022, 10, 442.	2.1	21

#	Article	IF	Citations
360	Genetic Characteristics of Porcine Hemagglutinating Encephalomyelitis Coronavirus: Identification of Naturally Occurring Mutations Between 1970 and 2015. Frontiers in Microbiology, 2022, 13, 860851.	1.5	1
361	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). Frontiers in Immunology, 2022, 13, 865401.	2.2	8
363	Nanomedicines Targeting Respiratory Injuries for Pulmonary Disease Management. Advanced Functional Materials, 2022, 32, .	7.8	9
364	Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms. Molecular Biology Reports, 2022, 49, 4943-4957.	1.0	29
365	Identification of Linear B Cell Epitopes on CD2V Protein of African Swine Fever Virus by Monoclonal Antibodies. Microbiology Spectrum, 2022, 10, e0105221.	1.2	8
366	A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerging Microbes and Infections, 2022, 11, 1058-1071.	3.0	63
367	Exploratory assessment of serological tests to determine antibody titer against SARSâ€CoVâ€2: Appropriateness and limits. Journal of Clinical Laboratory Analysis, 2022, 36, e24363.	0.9	6
368	Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?. Journal of Virology, 2022, 96, jvi0207721.	1.5	143
369	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. MBio, 2022, 13, e0297921.	1.8	117
370	The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines. Mini-Reviews in Medicinal Chemistry, 2022, 22, 2166-2185.	1.1	3
371	Safety and Efficacy of the Common Vaccines against COVID-19. Vaccines, 2022, 10, 513.	2.1	27
372	A rapid bead-based assay for screening of SARS-CoV-2 neutralizing antibodies. Antibody Therapeutics, 2022, 5, 100-110.	1.2	3
373	SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments. Therapeutic Delivery, 2022, 13, 187-203.	1.2	8
374	Tuftsin: A Natural Molecule Against SARS-CoV-2 Infection. Frontiers in Molecular Biosciences, 2022, 9, 859162.	1.6	5
375	Global trends in COVID-19. , 2022, 1, 31-39.		8
376	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. Cells, 2022, 11, 1182.	1.8	10
377	Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines. Advanced Materials, 2022, 34, e2107946.	11.1	10
378	COVID-19 vaccination: The road ahead. Science, 2022, 375, 1127-1132.	6.0	134

#	Article	IF	Citations
379	Antibody Response to SARS-CoV-2 in Relation to the Contributing Factors in COVID-19 Patients. Viral Immunology, 2022, 35, 142-149.	0.6	3
380	Nanotechnology and COVID-19: quo vadis?. Journal of Nanoparticle Research, 2022, 24, 62.	0.8	6
381	More efforts are needed for background surveys of zoonotic coronaviruses in animals. Cell Reports Medicine, 2022, 3, 100524.	3.3	1
382	Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One. Open Respiratory Medicine Journal, 2022, 16, .	1.3	0
383	Visualizing the efficacy of vaccination in different Indian states: a comparative account with other countries. VirusDisease, 2022, , 1-18.	1.0	0
384	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	4.9	27
385	Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation. The Lancet Regional Health - Western Pacific, 2022, 21, 100440.	1.3	5
386	COVID-19 Vaccination During Pregnancy. , 2022, 2, 1-7.		0
387	Fighting SARS-CoV-2 with structural biology methods. Nature Methods, 2022, 19, 381-383.	9.0	3
388	A New Wave of COVID-19 in 2021 with Unique Genetic Characters - Present Global Scenario and Beholding Onwards. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	4
389	From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life. Recent Patents on Biotechnology, 2022, 16, 2-5.	0.4	4
390	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. IScience, 2022, 25, 104043.	1.9	19
391	The basis of mink susceptibility to SARS-CoV-2 infection. Journal of Applied Genetics, 2022, 63, 543-555.	1.0	5
392	Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants. Virology, 2022, 569, 56-63.	1.1	6
393	The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic Applications in Depression and Anxiety. CNS and Neurological Disorders - Drug Targets, 2023, 22, 417-430.	0.8	2
394	A global survey in the developmental landscape of possible vaccination strategies for COVID-19. Clinical Immunology, 2022, 237, 108958.	1.4	11
395	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 â€“ a review. Translational Research, 2022, 242, 1-19.	2.2	3
396	The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMIRNATY vaccine (Pfizer/BioNTech). Scientific Reports, 2022, 12, 5999.	1.6	3

#	Article	IF	Citations
397	In-silico genomic landscape characterization and evolution of SARS-CoV-2 variants isolated in India shows significant drift with high frequency of mutations. Saudi Journal of Biological Sciences, 2022, 29, 3494-3501.	1.8	2
398	Discovery of 4â€²-O-methylscutellarein as a potent SARS-CoV-2 main protease inhibitor. Biochemical and Biophysical Research Communications, 2022, 604, 76-82.	1.0	9
399	Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models. Molecular Therapy - Methods and Clinical Development, 2022, 25, 225-235.	1.8	12
400	Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives. Borneo Journal of Pharmacy, 2021, 4, 311-323.	0.1	3
401	Sudden Cardiac Death Caused by Cardiac Small Vessel Vasculitis after COVID-19 Vaccination (BNT162b2) Tj ETQq0 0 0 rgBT /Overlock 1	0.1	2
405	A Narrative Review of COVID-19 Vaccines. Vaccines, 2022, 10, 62.	2.1	40
406	Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. Cell Discovery, 2021, 7, 123.	3.1	10
407	Pediatric Endoscopy During COVID-19 Times. Frontiers in Pediatrics, 2021, 9, 750717.	0.9	1
408	Functionalized Terpolymer-Brush-Based Biointerface with Improved Antifouling Properties for Ultra-Sensitive Direct Detection of Virus in Crude Clinical Samples. ACS Applied Materials & Interfaces, 2021, 13, 60612-60624.	4.0	19
409	Aptamer Sandwich Assay for the Detection of SARS-CoV-2 Spike Protein Antigen. ACS Omega, 2021, 6, 35657-35666.	1.6	27
410	Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. Open Forum Infectious Diseases, 2022, 9, ofab632.	0.4	30
411	COVID-19 Pandemic: Outbreak, Potential Vaccines And Medications. Russian Open Medical Journal, 2021, 10, .	0.1	0
412	Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. Vaccines, 2022, 10, 23.	2.1	37
413	Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. Current Neuropharmacology, 2022, 20, 1811-1815.	1.4	1
414	High-Yield Production of Receptor Binding Domain of SARS-CoV-2 Linked to Bacterial Flagellin in Plants Using Self-Replicating Viral Vector pEff. Plants, 2021, 10, 2682.	1.6	10
415	Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant B. subtilis on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate. Vaccines, 2022, 10, 2.	2.1	7
416	Aptamers for SARSâ€CoVâ€2: Isolation, Characterization, and Diagnostic and Therapeutic Developments. Analysis & Sensing, 2022, 2, .	1.1	17
418	Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern. Vaccines, 2022, 10, 578.	2.1	7

#	Article	IF	Citations
419	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. Journal of Virology, 2022, 96, e0005722.	1.5	14
420	Altered Expression of ACE2 and Co-receptors of SARS-CoV-2 in the Gut Mucosa of the SIV Model of HIV/AIDS. Frontiers in Microbiology, 2022, 13, 879152.	1.5	0
421	SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals. Vaccines, 2022, 10, 643.	2.1	8
422	COVID-19 Vaccines: Current and Future Perspectives. Vaccines, 2022, 10, 608.	2.1	26
423	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. Vaccines, 2022, 10, 591.	2.1	27
424	Robust Mutation Profiling of SARS-CoV-2 Variants from Multiple Raw Illumina Sequencing Data with Cloud Workflow. Genes, 2022, 13, 686.	1.0	7
425	Multimodal Benefits of Exercise in Patients With Multiple Sclerosis and COVID-19. Frontiers in Physiology, 2022, 13, 783251.	1.3	3
426	Personality Effects on Chinese Public Preference for the COVID-19 Vaccination: Discrete Choice Experiment and Latent Profile Analysis Study. International Journal of Environmental Research and Public Health, 2022, 19, 4842.	1.2	7
427	Oral Immunization of Mice with Cell Extracts from Recombinant Lactococcus lactis Expressing SARS-CoV-2 Spike Protein. Current Microbiology, 2022, 79, 167.	1.0	6
428	Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. International Journal of Biological Macromolecules, 2022, 209, 1359-1367.	3.6	3
429	The Case for Acquired Immunity as a Strategy to Thwart SARS-CoV-2 Virus Infection. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 51-52.	0.8	0
430	COVID-19 serological evaluation in a cohort of Vaccinated and Seropositive healthcare workers. Acta Biomedica, 2021, 92, e2021415.	0.2	4
431	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, E. coli Ribonuclease I and Human RNase A. Frontiers in Microbiology, 2021, 12, 660149.	1.5	1
432	Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment.. American Journal of Translational Research (discontinued), 2022, 14, 2063-2072.	0.0	0
434	COVID-19 vaccines and coronavirus 19 variants including alpha, delta, and omicron: present status and future directions. , 0, 2, .		7
435	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. Viruses, 2022, 14, 854.	1.5	5
437	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell, 2022, 185, 2265-2278.e14.	13.5	77
438	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. Frontiers in Immunology, 2022, 13, 843928.	2.2	25

#	Article	IF	Citations
439	One Solution for All: Searching for Universal Aptamers for Constantly Mutating Spike Proteins of SARSâ€CoVâ€2. ChemMedChem, 2022, 17, .	1.6	7
440	Recent developments in SARSâ€CoVâ€2 vaccines: A systematic review of the current studies. Reviews in Medical Virology, 2023, 33, e2359.	3.9	17
441	Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166432.	1.8	8
442	Adaptive Immune Responses and Immunity to SARS-CoV-2. Frontiers in Immunology, 2022, 13, .	2.2	39
443	COVIDâ€'19: Main findings after a year and half of unease and the proper scientific progress (Review). Experimental and Therapeutic Medicine, 2022, 23, .	0.8	5
444	Genetic and Structural Analysis of SARS-CoV-2 Spike Protein for Universal Epitope Selection. Molecular Biology and Evolution, 2022, 39, .	3.5	7
445	Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review. Cureus, 2022, , .	0.2	3
446	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
447	Efficacy and Safety of the RBD-Dimerâ€"Based Covid-19 Vaccine ZF2001 in Adults. New England Journal of Medicine, 2022, 386, 2097-2111.	13.9	147
448	A Review of Different Vaccines and Strategies to Combat COVID-19. Vaccines, 2022, 10, 737.	2.1	8
449	BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and Andes orthohantavirus. Vaccines, 2022, 10, 721.	2.1	12
450	Development of DNA Vaccine Candidate against SARS-CoV-2. Viruses, 2022, 14, 1049.	1.5	7
451	Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges. Pharmaceutics, 2022, 14, 1066.	2.0	11
452	A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection. European Journal of Human Genetics, 2022, 30, 889-898.	1.4	30
453	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. Expert Review of Vaccines, 2022, 21, 1071-1086.	2.0	3
455	Influence of SARS-CoV-2 inactivation by different chemical reagents on the humoral response evaluated in a murine model. Molecular Immunology, 2022, 147, 199-208.	1.0	4
456	Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron Subvariants BA.1 and BA.2. SSRN Electronic Journal, 0, , .	0.4	0
457	COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries. Vaccine, 2022, 40, 5302-5312.	1.7	5

#	Article	IF	Citations
458	Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies. Biomedicines, 2022, 10, 1260.	1.4	6
459	Safety of COVID-19 vaccines in patients with non-communicable diseases: a protocol for systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2022, 12, e057233.	0.8	0
462	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. Medical Review, 2022, 2, 169-196.	0.3	5
463	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. International Reviews of Immunology, 2023, 42, 393-414.	1.5	26
464	Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore. Antibodies, 2022, 11, 38.	1.2	4
465	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Reports, 2022, 39, 110924.	2.9	20
466	A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. International Journal of Molecular Sciences, 2022, 23, 6123.	1.8	9
467	Transchromosomic bovinesâ€derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARSâ€CoVâ€2, MERSâ€CoV, Ebola, Zika, HIVâ€1, and influenza A virus. Journal of Medical Virology, 2022, 94, 4599-4610.	2.5	6
468	Mapping of SARS-CoV-2 spike protein evolution during the first and second waves of COVID-19 infections in India. Future Virology, 2022, 17, 557-575.	0.9	2
470	Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?. Frontiers in Immunology, 2022, 13, .	2.2	15
471	Impact of ChAdOx1 nCoV-19 (Covishieldâ„¢) Vaccination: How Long Will It Persist?. International Journal of Microbiology, 2022, 2022, 1-7.	0.9	1
472	Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design. Vaccines, 2022, 10, 841.	2.1	0
473	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. Molecular Immunology, 2022, 149, 107-118.	1.0	2
474	Imaging Severity COVID-19 Assessment in Vaccinated and Unvaccinated Patients: Comparison of the Different Variants in a High Volume Italian Reference Center. Journal of Personalized Medicine, 2022, 12, 955.	1.1	9
475	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. Vaccines, 2022, 10, 909.	2.1	6
476	Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell, 2022, 185, 2952-2960.e10.	13.5	96
477	Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern. ACS Infectious Diseases, 2022, 8, 1367-1375.	1.8	7
478	Codelivery of SARS-CoV-2 Prefusion-Spike Protein with CBLB502 by a Dual-Chambered Ferritin Nanocarrier Potentiates Systemic and Mucosal Immunity. ACS Applied Bio Materials, 2022, 5, 3329-3337.	2.3	1

#	Article	IF	Citations
479	Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients. International Journal of General Medicine, 0, Volume 15, 5693-5700.	0.8	1
480	COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity. Archives of Virology, 0, , .	0.9	1
481	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine, 2022, 28, 1715-1722.	15.2	29
482	Overview of SARS-CoV-2 and possible targets for the management of COVID-19 infections. Coronaviruses, 2022, 03, .	0.2	0
483	Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. Journal of Virology, 0, , .	1.5	3
485	Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease. Scientific Reports, 2022, 12, .	1.6	2
486	Nanoarchitectonics: role of nanomaterials in vaccination strategies for curbing SARs-CoV-2/COVID-19. Nanofabrication, 0, 7, .	1.1	0
487	Rapid and accurate identification of SARS-CoV-2 Omicron variants using droplet digital PCR (RT-ddPCR). Journal of Clinical Virology, 2022, 154, 105218.	1.6	12
488	Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic. Journal of Zhejiang University: Science B, 2022, 23, 451-460.	1.3	7
489	A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. Translational Research, 2022, 249, 13-27.	2.2	5
490	Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic. Biosafety and Health, 2022, 4, 347-363.	1.2	2
491	Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	12
493	A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China. International Journal of Medical Sciences, 2022, 19, 1122-1130.	1.1	0
494	Ã...ngstrom-scale silver particles potently combat SARS-CoV-2 infection by suppressing the ACE2 expression and inflammatory responses. Journal of Materials Chemistry B, 2022, 10, 5454-5464.	2.9	4
495	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	59
496	Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection. Frontiers in Pharmacology, 0, 13, .	1.6	3
497	Short-Term Side Effects and SARS-CoV-2 Infection after COVID-19 Pfizerâ€“BioNTech Vaccine in Children Aged 5â€“11 Years: An Italian Real-World Study. Vaccines, 2022, 10, 1056.	2.1	12
498	The humoral response and antibodies against SARS-CoV-2 infection. Nature Immunology, 2022, 23, 1008-1020.	7.0	84

#	Article	IF	Citations
499	Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant. Frontiers in Immunology, 0, 13, .	2.2	6
500	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. Communications Biology, 2022, 5, .	2.0	26
501	Advances in Infectious Disease Vaccine Adjuvants. Vaccines, 2022, 10, 1120.	2.1	32
502	Assessment of hypokalemia and clinical prognosis in Patients with COVID-19 in Yangzhou, China. PLoS ONE, 2022, 17, e0271132.	1.1	3
503	The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	47
505	Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination. Biosafety and Health, 2022, 4, 228-233.	1.2	6
506	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. International Immunology, 2022, 34, 595-607.	1.8	19
507	The First Approved COVID-19 Vaccines: The Road to Cancer Vaccines. International Journal of Translational Medicine, 2022, 2, 309-331.	0.1	0
508	Presumably Corneal Graft Rejection after COVID-19 Vaccination. Case Reports in Ophthalmology, 2022, 13, 562-569.	0.3	6
509	Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals. Science Translational Medicine, 2023, 15, .	5.8	22
510	Evolution of the SARSâ€CoVâ€2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Reviews in Medical Virology, 2022, 32, .	3.9	276
511	Temperature-Responsive Liposome-Linked Immunosorbent Assay for the Rapid Detection of SARS-CoV-2 Using Immunoliposomes. ACS Omega, 2022, 7, 26936-26944.	1.6	3
512	Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Science Translational Medicine, 2022, 14, .	5.8	38
513	Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. Cell Host and Microbe, 2022, 30, 1255-1268.e5.	5.1	45
514	A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review. Internal Medicine, 2022, 61, 3101-3106.	0.3	13
515	In Silico Analysis of the Effects of Omicron Spike Amino Acid Changes on the Interactions with Human Proteins. Molecules, 2022, 27, 4827.	1.7	2
516	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. International Journal of Molecular Sciences, 2022, 23, 8485.	1.8	6
517	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Frontiers in Immunology, 0, 13, .	2.2	16

#	Article	IF	Citations
521	Global pandemic perspectives: public health, mental health, and lessons for the future. Lancet, The, 2022, 400, e3-e7.	6.3	16
522	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nature Communications, 2022, 13, .	5.8	12
523	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. Journal of Clinical Immunology, 2023, 43, 31-45.	2.0	4
524	Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine. Frontiers in Immunology, 0, 13, .	2.2	2
525	A study protocol to prepare an RBD protein for vaccine against COVID-19. F1000Research, 0, 10, 943.	0.8	0
526	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. Science Translational Medicine, 2022, 14, .	5.8	15
527	Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. MBio, 2022, 13, .	1.8	18
528	Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model. Travel Medicine and Infectious Disease, 2022, 49, 102427.	1.5	0
529	Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. International Journal of Biological Macromolecules, 2022, 219, 980-997.	3.6	28
530	From vaccines to nanovaccines: A promising strategy to revolutionize rheumatoid arthritis treatment. Journal of Controlled Release, 2022, 350, 107-121.	4.8	9
531	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. International Immunopharmacology, 2022, 111, 109161.	1.7	9
532	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. International Immunopharmacology, 2022, 111, 109128.	1.7	9
533	BBIBP-CorV Vaccination Reduces COVID-19 Severity Rate and Accelerates Anti-Viral Antibody Responses in Heterologous Omicron Infection. SSRN Electronic Journal, 0, , .	0.4	0
534	Salivary SARS-CoV-2 antibody detection using S1-RBD protein-immobilized 3D melt electrowritten poly(Îµ-caprolactone) scaffolds. RSC Advances, 2022, 12, 24849-24856.	1.7	7
535	Humoral Immune Response in SARS-CoV-2 Infection and Its Therapeutic Relevance. , 2022, , 19-29.		0
536	Computational biology and biosensors as surveillance tools for emerging and re-emerging infectious diseases. , 2022, , 419-441.		0
537	Analytical performances of different diagnostic methods for SARS-CoV-2 virus - A review. Sensors International, 2022, 3, 100197.	4.9	2
538	Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. Journal of Immunology Research, 2022, 2022, 1-9.	0.9	11

#	Article	IF	Citations
541	A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals. Microorganisms, 2022, 10, 1812.	1.6	2
542	SARS-CoV-2 Invasion and Pathological Links to Prion Disease. Biomolecules, 2022, 12, 1253.	1.8	7
543	A replication-competent smallpox vaccine LC16m8Î”-based COVID-19 vaccine. Emerging Microbes and Infections, 2022, 11, 2359-2370.	3.0	5
544	mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2. Cell Research, 2022, 32, 1022-1025.	5.7	10
545	Drug repurposing and sequence analysis in S-glycoprotein variants reveals critical signature patterns and destabilization of receptor-binding domain in omicron variant. Journal of Biomolecular Structure and Dynamics, 2023, 41, 7931-7948.	2.0	0
547	Towards the development of an epitope-focused vaccine for SARS-CoV-2. Vaccine, 2022, 40, 6489-6498.	1.7	3
548	Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Emerging Microbes and Infections, 2022, 11, 2412-2422.	3.0	10
549	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. Infectious Diseases, 0, , .	4.0	0
550	A study protocol to prepare an RBD protein for vaccine against COVID-19. F1000Research, 0, 10, 943.	0.8	0
551	Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine. Cell Reports Medicine, 2022, 3, 100752.	3.3	14
552	Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection. Cell Reports Medicine, 2022, 3, 100764.	3.3	16
553	Designing multi-epitope based peptide vaccine targeting spike protein SARS-CoV-2 B1.1.529 (Omicron) variant using computational approaches. Structural Chemistry, 2022, 33, 2243-2260.	1.0	6
554	Effect of inactivated COVID-19 vaccination on intrauterine insemination cycle success: A retrospective cohort study. Frontiers in Public Health, 0, 10, .	1.3	1
555	Potential of Azadirachta indica as a Capping Agent for Antiviral Nanoparticles against SARS-CoV-2. BioMed Research International, 2022, 2022, 1-12.	0.9	6
556	Psychological determinants of COVID-19 vaccine acceptance among urban slum dwellers of Bangladesh. Frontiers in Public Health, 0, 10, .	1.3	5
557	Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants. Protein Journal, 2022, 41, 457-467.	0.7	0
559	Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2. Viruses, 2022, 14, 2020.	1.5	1
560	Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus. International Journal of Molecular Sciences, 2022, 23, 11131.	1.8	8

#	Article	IF	Citations
561	COVID-19 Vaccines Adverse Reactions Reported to the Pharmacovigilance Unit of Beira Interior in Portugal. Journal of Clinical Medicine, 2022, 11, 5591.	1.0	3
562	Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine. Frontiers in Immunology, 0, 13, .	2.2	4
563	COVID-19 Vaccinating Russian Medical Studentsâ€"Challenges and Solutions: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 11556.	1.2	2
564	SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. Viruses, 2022, 14, 1966.	1.5	6
565	A retrospective analysis of respiratory virus transmission before and during the COVID-19 pandemic in Pune the western region of India. Frontiers in Public Health, 0, 10, .	1.3	4
566	IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA. Frontiers in Immunology, 0, 13, .	2.2	12
567	SARS-CoV-2, long COVID, prion disease and neurodegeneration. Frontiers in Neuroscience, 0, 16, .	1.4	6
568	Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nature Reviews Immunology, 2023, 23, 189-199.	10.6	112
569	A critical overview of current progress for COVID-19: development of vaccines, antiviralÂdrugs, and therapeutic antibodies. Journal of Biomedical Science, 2022, 29, .	2.6	64
571	Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. EBioMedicine, 2022, 83, 104240.	2.7	5
572	Localized delivery of nanomedicine and antibodies for combating COVID-19. Acta Pharmaceutica Sinica B, 2023, 13, 1828-1846.	5.7	5
573	Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Frontiers in Immunology, 0, 13, .	2.2	21
574	Development of variantâ€proof severe acute respiratory syndrome coronavirus 2, panâ€sarbecovirus, and panâ€²â€coronavirus vaccines. Journal of Medical Virology, 2023, 95, .	2.5	12
575	Seroprevalence of SARS-CoV-2 in Mexican Health Care Workers after Two Years of the Pandemic: The Picture of an Ophthalmic Medical Centre. Ophthalmic Epidemiology, 2023, 30, 400-406.	0.8	2
576	Adaptationâ€Proof SARSâ€CoVâ€2 Vaccine Design. Advanced Functional Materials, 2022, 32, .	7.8	7
577	Nanovaccines to combat virusâ€related diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	3
579	Monkeypox: Emerging virus of concern; antivirals and vaccines therapeutic options. Microbial Pathogenesis, 2022, 173, 105799.	1.3	4
580	Adjuvants to increase immunogenicity of SARS-CoV-2 RBD and support maternalâ€"fetal transference of antibodies in mice. Pathogens and Disease, 2022, 80, .	0.8	1

#	Article	IF	Citations
581	Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study. Vaccines, 2022, 10, 1706.	2.1	3
582	A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern. , 2022, 19, 1279-1289.		15
583	Mapping Potential Vaccine Candidates Predicted by VaxiJen for Different Viral Pathogens between 2017â€“2021â€”A Scoping Review. Vaccines, 2022, 10, 1785.	2.1	5
584	Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (CovishieldÂ®) in Patients with Liver Cirrhosis. Vaccines, 2022, 10, 1837.	2.1	6
585	Development of Single-Cell Transcriptomics and Its Application in COVID-19. Viruses, 2022, 14, 2271.	1.5	1
586	SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing. Virology Journal, 2022, 19, .	1.4	5
587	Design Strategies for and Stability of mRNAâ€“Lipid Nanoparticle COVID-19 Vaccines. Polymers, 2022, 14, 4195.	2.0	13
588	Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses. Vaccines, 2022, 10, 1805.	2.1	3
589	Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients. Vaccines, 2022, 10, 1693.	2.1	5
591	Omics tools enabling vaccine discovery against fasciolosis. Trends in Parasitology, 2022, 38, 1068-1079.	1.5	5
592	Zebrafish models of COVID-19. FEMS Microbiology Reviews, 2023, 47, .	3.9	6
593	TGF-Î²1 contributes to the hepatic inflammation in animal models with nonalcoholic steatohepatitis by Smad3/TLR2 signaling pathway. Molecular Immunology, 2022, 152, 129-139.	1.0	2
594	Antiviral biomaterials. , 2023, , 519-536.		0
595	Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. Infectious Diseases and Therapy, 2023, 12, 177-191.	1.8	2
596	Molecular Docking and Dynamics Simulation Studies of Ginsenosides with SARS-CoV-2 Host and Viral Entry Protein Targets. Natural Product Communications, 2022, 17, 1934578X2211343.	0.2	3
597	Rational Development of Hypervalent Glycan Shieldâ€Binding Nanoparticles with Broadâ€Spectrum Inhibition against Fatal Viruses Including SARSâ€CoVâ€2 Variants. Advanced Science, 2023, 10, .	5.6	10
598	Assessment of cell-mediated immune responses to SARS-CoV-2 in Syrian hamsters. Meditsinskii Akademicheskii Zhurnal, 2022, 2, 215-220.	0.2	1
599	Epidemiological Analysis of COVID-19 Outbreaks in Wuhu, China, from January to March 2020. Jundishapur Journal of Microbiology, 2022, 15, .	0.2	1

#	Article	IF	Citations
600	Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan. Frontiers in Immunology, 0, 13, .	2.2	3
601	Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach. Molecules, 2022, 27, 7522.	1.7	5
602	A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein. Cell Research, 2022, 32, 1068-1085.	5.7	27
603	Longâ€term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVacâ€inactivated booster: A 7â€month followâ€up study. Journal of Medical Virology, 2023, 95, .	2.5	3
604	The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults. Frontiers in Microbiology, 0, 13, .	1.5	2
605	Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3â€“9-month intervals following two-dose inactivated vaccine (CoronaVac). Frontiers in Immunology, 0, 13, .	2.2	5
606	A review of COVID vaccines: success against a moving target. British Medical Bulletin, 2022, 144, 12-44.	2.7	5
607	Characterization and analysis of linear epitopes corresponding to SARSâ€CoVâ€2 outbreak in Jilin Province, China. Journal of Medical Virology, 2023, 95, .	2.5	4
608	Incidence and outcomes of splanchnic vein thrombosis after diagnosis of COVID-19 or COVID-19 vaccination: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2023, 55, 18-31.	1.0	4
609	An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. Frontiers in Microbiology, 0, 13, .	1.5	4
610	A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice. Materials Horizons, 2023, 10, 466-472.	6.4	4
611	Covid-19: evoluÃ§Ã£o temporal e imunizaÃ§Ã£o nas trÃªs ondas epidemiolÃ³gicas, Brasil, 2020â€“2022. Revista De Saude Publica, 0, 56, 105.	0.7	12
612	Comparison of machine learning methods with logistic regression analysis in creating predictive models for risk of critical in-hospital events in COVID-19 patients on hospital admission. BMC Medical Informatics and Decision Making, 2022, 22, .	1.5	7
613	SARS-CoV-2 in brief: from virus to prevention. Osong Public Health and Research Perspectives, 2022, 13, 394-406.	0.7	1
614	As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?. Frontiers in Public Health, 0, 10, .	1.3	5
615	Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination. Emerging Microbes and Infections, 2023, 12, .	3.0	13
616	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
617	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions, 2022, 50, 1643-1658.	1.6	6

#	Article	IF	Citations
618	Involvement of the STING signaling in COVID-19. Frontiers in Immunology, 0, 13, .	2.2	3
619	Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs after Vaccination (DANTE-SIRIO 7) Study in a Large Cohort of Healthcare Workers. Vaccines, 2022, 10, 2125.	2.1	0
620	Design and performance characteristics of the Elecsys anti-SARS-CoV-2 S assay. Frontiers in Immunology, 0, 13, .	2.2	6
621	Developing Biosensors for SARS-CoV-2 Wastewater-Based Epidemiology: A Systematic Review of Trends, Limitations and Future Perspectives. Sustainability, 2022, 14, 16761.	1.6	2
622	Knowledge And Attitudes Toward the COVID-19 Vaccine Among India's General Rural Population. Vacunas, 2022, , .	1.1	0
623	Structural Characteristics of Heparin Binding to SARS-CoV-2 Spike Protein RBD of Omicron Sub-Lineages BA.2.12.1, BA.4 and BA.5. Viruses, 2022, 14, 2696.	1.5	8
624	Urgent Need for Next-Generation COVID-19 Vaccines. JAMA - Journal of the American Medical Association, 2023, 329, 19.	3.8	25
625	High-Yield Production of Chimeric Hepatitis E Virus-Like Particles Bearing the M2e Influenza Epitope and Receptor Binding Domain of SARS-CoV-2 in Plants Using Viral Vectors. International Journal of Molecular Sciences, 2022, 23, 15684.	1.8	8
626	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. Expert Review of Vaccines, 2023, 22, 35-53.	2.0	8
627	Multipolymer microsphere delivery of SARS-CoV-2 antigens. Acta Biomaterialia, 2023, 158, 493-509.	4.1	4
628	The prevalence of SARS-CoV-2 antibodies within the community of a private tertiary university in the Philippines: A serial cross sectional study. PLoS ONE, 2022, 17, e0268145.	1.1	2
629	Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses. Frontiers in Immunology, 0, 13, .	2.2	1
630	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Scientific Reports, 2022, 12, .	1.6	5
631	Immune Responses against the Omicron Variant of SARS-CoV-2 after a Third Dose of COVID-19 Vaccine in Patients Living with Human Immunodeficiency Virus (PLWH): Comparison with Healthcare Workers. Vaccines, 2022, 10, 2129.	2.1	5
632	Therapeutic potential of compounds targeting SARS-CoV-2 helicase. Frontiers in Chemistry, 0, 10, .	1.8	3
634	Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations. Pathogens, 2023, 12, 20.	1.2	4
635	Key mutations in the spike protein of SARSâ€CoVâ€2 affecting neutralization resistance and viral internalization. Journal of Medical Virology, 2023, 95, .	2.5	15
636	Parentsâ€™ Level of COVID-19 Fear, Anxiety and Their Attitudes and Behaviors Toward Vaccination of Their Children. Omega: Journal of Death and Dying, 0, , 003022282211463.	0.7	0

#	Article	IF	Citations
637	Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster. Microbes and Infection, 2023, 25, 105101.	1.0	3
638	The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. Journal of Inflammation Research, 0, Volume 16, 145-160.	1.6	5
639	Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. International Journal of Molecular Sciences, 2023, 24, 1701.	1.8	5
640	A Facile Method to Coat Nanoparticles with Lipid Bilayer Membrane: Hybrid Silica Nanoparticles Disguised as Biomembrane Vesicles by Particle Penetration of Concentrated Lipid Layers. Small, 2023, 19, .	5.2	4
641	Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation. International Journal of Molecular Sciences, 2023, 24, 908.	1.8	6
642	Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. Nature Microbiology, 2023, 8, 121-134.	5.9	6
643	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. Biomedical Journal, 2023, 46, 70-80.	1.4	8
644	Performance of the SureScreen Diagnostics COVID-19 antibody rapid test in comparison with three automated immunoassays.. Diagnostic Microbiology and Infectious Disease, 2023, , 115900.	0.8	0
645	Polypharmacology of ambroxol in the treatment of COVID-19. Bioscience Reports, 0, , .	1.1	0
646	A vaccine delivery system promotes strong immune responses against SARSâ€CoVâ€2 variants. Journal of Medical Virology, 2023, 95, .	2.5	6
647	Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 361-381.	0.2	2
648	Characterization of SARS-CoV-2 omicron variants from Iran and evaluation of the effect of mutations on the spike, nucleocapsid, ORF8, and ORF9b proteins function. Journal of Biomolecular Structure and Dynamics, 2023, 41, 11415-11430.	2.0	2
650	An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV. Virologica Sinica, 2023, 38, 244-256.	1.2	3
651	The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine. Viruses, 2023, 15, 95.	1.5	8
652	Diabetes Prevention and Measures to Ensuring a Healthy Lifestyle during COVID-19 Pandemic and after. Korean Journal of Family Medicine, 2023, 44, 11-20.	0.4	1
653	Machine-learning prediction of BMI change among doctors and nurses in North China during the COVID-19 pandemic. Frontiers in Nutrition, 0, 10, .	1.6	1
654	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. Bioengineering, 2023, 10, 148.	1.6	3
655	Applications of genetic engineering in COVID-19. , 2023, , 219-237.		0

#	Article	IF	Citations
656	Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection. Cell Reports Physical Science, 2023, , 101249.	2.8	1
657	Humoral Immune Response to CoronaVac in Turkish Adults. Vaccines, 2023, 11, 216.	2.1	1
658	Displaying and delivering viral membrane antigens via WW domainâ€“activated extracellular vesicles. Science Advances, 2023, 9, .	4.7	6
659	SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. Diagnostics, 2023, 13, 559.	1.3	12
660	Advances in Vaccine Adjuvants: Nanomaterials and Small Molecules. Handbook of Experimental Pharmacology, 2023, , .	0.9	0
661	COVID-19 Vaccination in Korea. Infection and Chemotherapy, 2023, 55, 135.	1.0	9
663	PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application. Npj Vaccines, 2023, 8, .	2.9	0
664	An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. Progress in Biophysics and Molecular Biology, 2023, 178, 32-49.	1.4	16
665	Tracking the COVID-19 vaccines: The global landscape. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	17
666	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. Journal of Molecular Modeling, 2023, 29, .	0.8	4
667	Adaptive Evolution of the Spike Protein in Coronaviruses. Molecular Biology and Evolution, 2023, 40, .	3.5	6
668	Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment. Life Sciences, 2023, 320, 121525.	2.0	2
669	Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus. Vaccine, 2023, 41, 3337-3346.	1.7	1
670	Antibody isotype epitope mapping of SARSâ€CoVâ€2 Spike RBD protein: Targets for COVIDâ€19 symptomatology and disease control. European Journal of Immunology, 2023, 53, .	1.6	2
671	SARS-CoV-2 variants-associated outbreaks of COVID-19 in a tertiary institution, North-Central Nigeria: Implications for epidemic control. PLoS ONE, 2023, 18, e0280756.	1.1	0
672	Sequential orbital apex syndrome following the COVID-19 vaccination: A case report. ENeurologicalSci, 2023, 30, 100447.	0.5	1
673	Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. IScience, 2023, 26, 106126.	1.9	9
674	Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study. Frontiers in Immunology, 0, 14, .	2.2	2

#	Article	IF	Citations
675	Bacillus subtilis spores displaying RBD domain of SARS-CoV-2 spike protein. Computational and Structural Biotechnology Journal, 2023, 21, 1550-1556.	1.9	5
676	Government Policy in Strengthening Innovative Ecosystem as the Representation of Integration and Collaboration in Covid-19 Prevention and Handling in Surakarta Indonesia. , 2022, , 7-14.		0
677	Possible menstrual cycle changes after COVID 19 vaccination a questionnaire-based study among vaccinated women. Annals of Geriatric Education and Medical Sciences, 2023, 9, 58-63.	0.1	0
678	The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution. ELife, 0, 12, .	2.8	21
679	Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. PLoS ONE, 2023, 18, e0281689.	1.1	8
680	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 2023, 11, 432.	2.1	17
681	In Silico Studies to Support Vaccine Development. Pharmaceutics, 2023, 15, 654.	2.0	4
682	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity, 2023, 56, 669-686.e7.	6.6	43
683	Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3â€“17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. The Lancet Child and Adolescent Health, 2023, 7, 269-279.	2.7	6
684	Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis. American Journal of Infection Control, 2023, 51, 1049-1055.	1.1	4
685	Delivery of spike-RBD by bacterial type three secretion system for SARS-CoV-2 vaccine development. Frontiers in Immunology, 0, 14, .	2.2	1
686	ZF2001, A Protein Subunit Vaccines against SARS-CoV-2. , 0, , .		0
687	Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine. Biosafety and Health, 2023, 5, 89-100.	1.2	4
688	Variants of SARS-CoV-2: Influences on the Vaccinesâ€™ Effectiveness and Possible Strategies to Overcome Their Consequences. Medicina (Lithuania), 2023, 59, 507.	0.8	5
689	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. Frontiers in Immunology, 0, 14, .	2.2	1
690	Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19. JCI Insight, 2023, 8, .	2.3	1
691	Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants. Molecular Biomedicine, 2023, 4, .	1.7	0
692	Duplex Electrochemical Microfluidic Sensor for COVIDâ€19 Antibody Detection: Natural versus Vaccineâ€Induced Humoral Response. Small, 2023, 19, .	5.2	4

#	Article	IF	Citations
693	Tannic Acid Lipid Nanoparticles can Deliver Messenger RNA Payloads and Improve their Endosomal Escape. Advanced Therapeutics, 2023, 6, .	1.6	5
694	SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. Vaccines, 2023, 11, 682.	2.1	7
695	Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. Scientific Reports, 2023, 13, .	1.6	0
696	Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWEâ„¢. Vaccine, 2023, 41, 2793-2803.	1.7	4
697	The Focused Analysis of COVID-19 RNA-based vaccines. , 0, 36, 866-870.		0
698	Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. Frontiers of Medicine, 2023, 17, 562-575.	1.5	8
699	DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response. Communications Biology, 2023, 6, .	2.0	14
700	Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. ACS Nano, 2023, 17, 7017-7034.	7.3	1
701	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. Cureus, 2023, , .	0.2	1
702	Factors associated with medication interruption among outpatients with severe mental illness exposed to COVID-19. Frontiers in Public Health, 0, 11, .	1.3	0
703	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. Viruses, 2023, 15, 856.	1.5	10
704	Adjuvant-Free COVID-19 Vaccine with Glycoprotein Antigen Oxidized by Periodate Rapidly Elicits Potent Immune Responses. ACS Chemical Biology, 2023, 18, 915-923.	1.6	0
705	The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management. Frontiers in Public Health, 0, 11, .	1.3	4
706	Sars-escape network for escape prediction of SARS-COV-2. Briefings in Bioinformatics, 0, , .	3.2	0
707	The effect of Pickering emulsion adjuvants on the immune efficacy of the COVID-19 polypeptide vaccine. ChemPhysMater, 2023, , .	1.4	0
708	A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?. Vaccines, 2023, 11, 833.	2.1	0
709	Network pharmacology and molecular docking analysis on the mechanism of Cordyceps militaris polysaccharide regulating immunity through TLR4/TNFâ€Î± pathwayss. Journal of Biochemical and Molecular Toxicology, 2023, 37, .	1.4	3
710	BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai. Vaccine, 2023, , .	1.7	2

#	Article	IF	Citations
711	Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine ConvacellÂ®. Vaccines, 2023, 11, 874.	2.1	2
717	Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	15
729	Two-birds-one-stone approach to combine protein and mRNA vaccines for COVID-19. Nature Immunology, 2023, 24, 1056-1057.	7.0	0
763	Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2. Immunologic Research, 0, , .	1.3	1
778	Harnessing Knowledge from COVID-19 Scenario for New Generation Vaccine Development to Control Pandemics in Animals. Livestock Diseases and Management, 2023, , 249-279.	0.5	0
788	Molecular testing in emerging infectious diseases. , 2024, , 175-198.		0
795	Managing COVID-19 Variants: Mapping Data from the International Clinical Trials Registry Platform. , 0, , .		1
802	Innovation-driven trend shaping COVID-19 vaccine development in China. Frontiers of Medicine, 2023, 17, 1096-1116.	1.5	0
808	Targets of SARS-CoV-2: therapeutic implications for COVID-19. , 2024, , 3-14.		0
811	Medical care for SARS-CoV-2. , 2024, , 159-173.		0